NLS Pharmaceutics Ltd. Warrant - NLSPW STOCK NEWS

NLS Pharmaceutics announced promising results from study KO-874, presented at the American Society of Clinical Psychopharmacology. The study evaluated mazindol's neuroprotective effects in a narcoleptic-like rat model. Key findings showed that a 3 mg/kg dose of mazindol significantly mitigated circadian activity reduction caused by OX-B-SAP lesions and restored activity levels to normal. Lower doses were less effective. The study highlights mazindol's potential utility in treating disorders like narcolepsy. Further clinical development is supported by these results.

NLS Pharmaceutics (NASDAQ: NLSP) announced it received an additional staff determination letter from Nasdaq on May 22, 2024, notifying the company of its non-compliance with the minimum $2,500,000 stockholders' equity requirement for continued listing. This additional delinquency serves as a separate basis for potential delisting. Previously, on April 19, 2024, NLS was informed of potential delisting due to failing to maintain a $1 bid price per share. The company has requested a hearing before a Nasdaq Hearings Panel, scheduled for June 4, 2024, to appeal the delisting determination and present its plans to regain compliance.

NLS Pharmaceutics received a delisting determination from Nasdaq due to failing to maintain a $1 bid price per share. The company plans to request a hearing to present a compliance plan and seek an extension to meet listing requirements. However, there is no guarantee of approval or regaining compliance.

NLS Pharmaceutics announced the closing of a registered direct offering of 7,000,000 common shares at $0.25 per share, raising $1.75 million. The company also issued unregistered warrants for 3,500,000 common shares at the same price. The proceeds will be used for working capital and general corporate purposes.

NLS Pharmaceutics announces a registered direct offering of 7,000,000 common shares at $0.25 per share, along with a private placement of unregistered warrants to purchase up to 3,500,000 common shares.

NLS Pharmaceutics (NLSP) announces a groundbreaking exclusive worldwide license agreement with Aexon Labs, Inc., acquiring global rights to Dual Orexin Receptor Agonists for neurological disorders. The agreement aims to develop compounds targeting orexin receptors for narcolepsy, hypersomnia, and neurodegenerative diseases. NLS plans to focus on disease-modifying compounds to enhance its neuroscience pipeline in sleep medicine.

NLS Pharmaceutics Ltd. announces CEO's attendance at BIO-EUROPE Springtime Partnering Event in Barcelona, Spain. The event aims to facilitate one-to-one meetings for over 3,700 attendees from 2,000+ companies.

NLS Pharmaceutics Ltd. (NLSP) regains compliance with Nasdaq listing requirements, given an additional 180 days to evidence compliance.

NLS Pharmaceutics Ltd. announces submission of plan to regain compliance with Nasdaq listing rule 5550(b)(1) after receiving notification of non-compliance due to minimum stockholders' equity requirement. Nasdaq may grant an extension of up to 180 days for compliance.